What Concerto Biosciences does

Concerto Biosciences is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, that measures, maps, and engineers microbial communities to develop therapies and consumer products across human health, food, and agricultural applications. The company's core asset is its integrated discovery platform comprising kChip, a patented MIT/Broad Institute-originated microwell array that physically constructs and measures millions of miniature microbial communities in parallel, and kAI, a proprietary artificial intelligence model trained on kChip-generated datasets to predict the behavior of untested microbial combinations. Together the platform has produced 40M+ microbial community measurements — including the 33M+ datapoint Skin Universe Project — forming the largest empirical microbial interaction dataset publicly described.

The company operates three product streams: ENS-002, a topical three-strain live biotherapeutic for atopic dermatitis that received FDA IND clearance in June 2024 and reported positive Phase 1b topline results in October 2025 (commercialized through partner Fermata Dermatologics); ENS-003, a discovery-stage live microbial candidate for recurrent vaginal yeast infection; and the CB-0XX consumer skin health ingredient portfolio addressing malodor, barrier strength, acne, and dandruff. Co-discovery and co-development agreements with partners such as Sacco System (food applications, signed January 2026) and Fermata Dermatologics (therapeutic development) provide commercial reach into consumer and biopharmaceutical channels.

Concerto's business model is a partnership-driven B2B platform play: revenue is expected to flow through licensing/royalties from co-discovery and co-development agreements, milestone payments from therapeutic out-licensing, and future ingredient supply to consumer skincare brands. Pricing is quote-based and bespoke, with no public price list. The company has raised approximately $47.5M across a 2022 SEC-registered securities offering ($24.54M) and a 2022 Series A ($23M led by Safar Partners with Horizons Ventures and M Ventures). Customer concentration is structurally high given the platform's reliance on a small number of named enterprise partners across each vertical.

Name

Concerto Biosciences

Legal name

Concerto Biosciences, Inc.

Website

https://concertobio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Concerto Biosciences is a clinical-stage biotech that uses its proprietary kChip screening platform and kAI model — trained on 40M+ proprietary microbial interaction measurements — to discover live biotherapeutic and consumer health products across dermatology, women's health, food, and agriculture, commercialized through B2B co-development partnerships with biotech, consumer, and food-industry companies.

Ownership category

akta.pro rank

Product category

Microbial Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures) (AFAJAJAF), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

Keywords

• Microbial discovery platform
• Live biotherapeutic products
• Microbiome ingredient discovery
• Microbial interaction analysis
• Consumer health ingredients

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Development and commercialization partnerships: Concerto signs co-discovery and co-development agreements with industry partners (e.g., Sacco System) that combine platform access and IP with partners' domain expertise, microbial collections, and commercial reach. Revenue mechanics likely include upfront, milestone, and downstream commercialization terms typical of biotech co-development deals.
2. B2B ingredient supply (CB-0XX, postbiotic ferments): Future/emerging revenue from supplying Concerto's proprietary microbe-based and postbiotic ferment ingredients to consumer skincare brands for deodorant, barrier, dandruff, and acne applications, enabled by partner go-to-market reach.
3. Therapeutic development and out-licensing (ENS-002): ENS-002 is being advanced via partner Fermata Dermatologics for atopic dermatitis; Concerto participates in therapeutic value capture through development collaborations and potential milestone/royalty economics as ENS-002 progresses through clinical trials.
4. Venture capital financing: Pre-commercial biotech supplemented by venture capital funding, including a $23M Series A led by Safar Partners with Horizons Ventures and M Ventures in November 2022 and an SEC Form D securities offering totaling approximately $24.54M.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Concerto Biosciences operates a microbial intelligence platform that combines kChip, a patented microwell array that physically constructs and measures millions of microbial communities in parallel, with kAI, a proprietary AI model trained on those datasets to predict behavior of untested microbial combinations. This platform powers the discovery of microbe-based products across three segments: clinical-stage live biotherapeutics (ENS-002 for atopic dermatitis), discovery-stage live microbial candidates (ENS-003 for recurrent vaginal yeast infection), and a consumer skin health ingredient portfolio (CB-0XX including CB-002 postbiotic ferment) addressing malodor, barrier strength, acne, and dandruff. Revenue is generated primarily through B2B co-discovery, co-development, and licensing partnerships with biotech, biopharma, food, and consumer care companies.

Product overview

Concerto Biosciences operates a single integrated platform-plus-product portfolio architecture anchored by its core discovery engine, kChip, and its proprietary AI model, kAI. kChip experimentally generates massive, high-quality datasets on microbial community behavior (>50M measurements), which train kAI to predict the behavior of untested microbe combinations. This intelligence platform feeds a portfolio of named products: the clinical-stage live biotherapeutic ENS-002 (topical three-strain product for atopic dermatitis, in development at Fermata Dermatologics); the discovery-stage ENS-003 (live microbial candidate for recurrent vaginal yeast infection); and the CB-0XX consumer skin health ingredient portfolio (including CB-002 postbiotic ferment), which addresses malodor, barrier strength, acne, and dandruff. The same platform is also deployed in co-discovery partnerships such as the Sacco System collaboration for next-generation food-grade microbial ingredients.

Differentiator

Problem solved

Functional benefit

Brands

• ENS-002: Three-strain topical live biotherapeutic product (Ensemble No.2) that pacifies Staphylococcus aureus virulence, in clinical development for atopic dermatitis.
• ENS-003
• CB-0XX
• CB-002

Products and services

• kChip MIT-developed, patented microwell array platform that physically constructs millions of miniature, defined microbial communities in parallel and captures direct functional readouts for every combination. Generates the empirical datasets that train kAI and underpin all of Concerto's microbe-based product discovery, solving the combinatorial bottleneck of conventional microbial screening. Made available to enterprise partners via co-discovery and co-development agreements.
• kAI Proprietary AI model of microbial ecology trained on kChip measurements (over 50M datapoints). Expands microbial interaction networks by predicting behavior of untested combinations, identifying synergistic and robust microbial communities for translation into real-world products. Powers hit generation across therapeutics, consumer products, and food applications, and is made available to enterprise partners as part of co-discovery and co-development agreements.
• ENS-002 Topical, three-strain live biotherapeutic product (Ensemble No.2) composed of skin-derived, clonal, commensal, non-pathogenic bacterial strains delivered at equal ratio. Designed to inhibit Staphylococcus aureus proliferation and virulence in atopic dermatitis without disrupting beneficial skin microbes. FDA IND-cleared June 2024; Phase 1b positive topline results announced October 2025 showing zero drug-related adverse events, dose-dependent EASI improvement, and targeted S. aureus suppression. In development at partner Fermata Dermatologics for further clinical advancement.
• ENS-003 Live microbial product candidate (Ensemble No.3) in kChip-based discovery for recurrent vulvovaginal candidiasis (vaginal yeast infection). Designed to inhibit Candida albicans virulence by reinforcing mechanisms of the natural protective vaginal microbiome, addressing a recurrent condition affecting over 1.5 million U.S. women with more than four symptomatic episodes per year.
• CB-0XX consumer skin health ingredient portfolio Portfolio of microbe-based ingredients for consumer skin health spanning solutions for malodor, skin barrier strength, acne, and dandruff. Discovered via kChip ultra-high-throughput microbial screening, with formulation types spanning live microbes, prebiotic nutrients, and postbiotic ferments. Includes CB-002, a postbiotic ferment formulated for consumer use targeting S. aureus-irritated skin. Supplied to consumer skincare and personal care brands for incorporation into retail products addressing deodorant, barrier support, dandruff, and acne care.

Quantifiable outcome

• 40M+ microbial communities constructed and measured (some references cite 50M+)
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Sacco SystemflagshipStrategic or Co-development Partner · 29 January 2026Concerto signed a development and commercialization agreement with Italian biotech group Sacco System on January 29, 2026 to advance next-generation microbial ingredient discovery for food, nutraceutical, pharmaceutical, and agro-veterinary applications. Sacco contributes its heritage library of food-grade cultures and applied food microbiology expertise; Concerto applies kChip technology to construct and measure millions of cocultures from Sacco's library and uses its kAI model to learn from those results. The collaboration aims to identify optimal strain synergies (1+1=3) for sustainable food production and deliver value to manufacturers and consumers. Concerto CEO Cheri Ackerman described it as setting a new standard for microbe-based product innovation.
• MIT / Broad InstitutecoreTechnology or Integration · 1 January 2020kChip was prototyped by Jared Kehe, Cheri Ackerman, and others at MIT and the Broad Institute, then licensed by Concerto after the cofounders incorporated the company in 2020. Foundational research published in PNAS (https://www.pnas.org/content/116/26/12804/).
• Fermata DermatologicscoreStrategic or Co-development PartnerFermata Dermatologics is commercializing ENS-002, Concerto's three-strain live biotherapeutic for atopic dermatitis, currently in clinical testing. The Products page directs partners to fermatadermatologics.com for more information on the program.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vedanta Biosciences: Clinical-stage developer of defined live biotherapeutic products manufactured from clonal bacterial strains. Directly comparable to Concerto's ENS-002 program in modality (defined-strain consortia) and indication strategy (inflammatory diseases), making it the closest head-to-head peer.
• Siolta Therapeutics: Clinical-stage microbiome therapeutics company focused on inflammatory diseases including atopic dermatitis. Comparable as a peer in the live biotherapeutic space targeting the same dermatology indication as Concerto's ENS-002.
• AOBiome: Developer of live bacterial therapeutic candidates for skin conditions, including acne and eczema. Comparable to Concerto on the dermatology microbiome indication axis and as a clinical-stage live biotherapeutics peer.
• S-Biomedic: Skin microbiome company developing live and postbiotic products for acne and other skin conditions. Comparable to Concerto's CB-0XX consumer skin health ingredient portfolio and the broader skin-microbiome commercial thesis.
• Second Genome: Microbiome-based drug discovery company using high-throughput screening and computational biology to identify microbe-derived therapeutics. Comparable as a platform-driven microbiome drug discovery peer applying similar combinatorial screening to Concerto's kChip approach.

Broad incumbents

• Seres Therapeutics: Pioneer and one of the most advanced microbiome therapeutics companies, with a recently approved live biotherapeutic and broader inflammatory/oncology pipeline. A larger incumbent offering overlapping capabilities in defined-strain microbiome therapeutics.
• Assembly Biosciences: Clinical-stage biotechnology company with a microbiome platform (distinct from its virology portfolio) targeting inflammatory diseases. Operates in the same defined-strain live biotherapeutic category as Concerto with greater scale and a broader pipeline.
• Rebiotix (Ferring Pharmaceuticals): Ferring's microbiome therapeutics subsidiary and pioneer of fecal-microbiota-based live biotherapeutics with an FDA-approved product (Rebyota). A broad incumbent in the live biotherapeutic space against which Concerto's defined-strain approach competes on precision.

Emerging players

• Eligo Bioscience: Developer of engineered microbiome-based therapeutics using phage-based delivery to modulate the microbiome. Comparable as a next-generation microbiome therapeutics peer with a more specialized (engineered) approach to microbial intervention.
• Novome Biotechnologies: Engineered microbial therapeutics company developing engineered consortia for hyperoxaluria and other indications. Comparable to Concerto on the engineered-microbial-consortium modality axis, though Novome's strain engineering is more genetically modified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/concertobio
• LinkedInlinkedin.com/company/concerto-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concerto Biosciences